Results 101 to 110 of about 190,081 (230)

The prognostic value of tumour budding for survival in stage II and III colorectal cancer: a systematic review and meta‐analysis

Histopathology, Volume 89, Issue 6, Page 927-940, December 2026.
This meta‐analysis demonstrates that high‐grade tumour budding is an independent prognostic factor in stage II–III colorectal cancer, associated with significantly worse disease‐free survival, overall survival and cancer‐specific survival. Aims Tumour budding (TB) has been recognized as an additional prognostic factor in the TNM (2017) and WHO (2019 ...
Yao Shu, Heng Zhang, Alessandro Lugli, Femke Simmer, Iris D. Nagtegaal   +4 more
wiley   +1 more source

Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the
Mary-Ellen Taplin, Steve Hentzen, Jacob S. Marzalik, Hamid Emamekhoo, Syed Arsalan Ahmed Naqvi, Thomas A. Hope, Fouad Nahhat, M. Hassan Murad, Huan He, Michael Thomas Serzan, Sebastien J. Hotte, R. Bryan Rumble, Rahul A. Parikh, Mariane Fontes Dias, Terry M. Kungel, Paul Celano, Irbaz Bin Riaz   +16 more
core   +1 more source

ASCO GI 2008

Onkologija, 2008
Ni abstrakta.
openaire   +2 more sources

Poorly differentiated lung adenocarcinomas with concurrent ALK and CD30 expression: a diagnostic pitfall mimicking ALK‐positive anaplastic large‐cell lymphoma

Histopathology, Volume 89, Issue 6, Page 1031-1041, December 2026.
Poorly differentiated lung adenocarcinomas with concurrent anaplastic lymphoma kinase (ALK) and CD30 expression closely mimic ALK‐positive anaplastic large‐cell lymphoma, creating a significant diagnostic pitfall. Accurate classification requires comprehensive integration of clinical, radiologic, morphologic, immunophenotypic and molecular findings ...
Jietian Jin, Wenjian Cen, Qin Yan, Yangshan Chen, Chaoyun Huang, Yanfeng Feng, Neng Jiang   +6 more
wiley   +1 more source

ASCO Domestic Quality Programs

JCO Global Oncology
A growing sense of the need to define good-quality cancer care has emerged in the past decade of the 20th century. The goals were to assess, improve, and reward quality.
Issam Makhoul, Steve Power, Catherine Smith, Traci Niece, Deirdre O'Mahony   +4 more
doaj   +1 more source

Navigating Asparaginase Treatment for Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations on the Role of Multidisciplinary Care

American Journal of Hematology, Volume 101, Issue 11, Page 2713-2725, November 2026.
ABSTRACT Asparaginase is a critical treatment component for patients with acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL). However, the successful delivery of asparaginase‐based therapy remains challenging across care settings due to its complex administration, distinct toxicity profile, prolonged treatment duration, and the need for ...
Amir Ali, Grace Elsey, Kayla Fulginiti, Zanette Kanani‐Bradley, Holly R. Kubaney, Sandra Kurtin, Theresa Nguyen, Jennifer Turchina, Charlotte B. Wagner   +8 more
wiley   +1 more source

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the
Bryan J. Schneider, Minaxi Jhawer, Paola Montenegro, Sarbajit Mukherjee, Erin B. Kennedy, Jacob S. Marzalik, Kohei Shitara, Dana Deighton, Christopher Nevala-Plagemann, Zahra Hamedi, Thomas Semrad, Melani Vincelli, Lakshmi Rajdev, Anwaar Saeed, Kunal C. Kadakia, Manish A. Shah   +15 more
core   +1 more source

Does Molecularly Guided Therapy Change the Surgical Goals of Glioma Resection?

Brain and Behavior, Volume 16, Issue 11, November 2026.
ABSTRACT Purpose For more than 20 years, the goal of glioma surgery has been to remove as much tumor as possible without compromising patient safety. Many retrospective studies support that greater extent of resection is often associated with longer survival. However, three recent developments have challenged this traditional approach.
Naeem Ul Haq, Sardar Umer Irshad, Irfan Ullah, Sardar Remsha Irshad, Shah Mir, Muhammad Shaheer Khan, Ali Mumtaz, Malik Ahsan Jamal, Jahan Mubariz   +8 more
wiley   +1 more source

Etiological classifications of transient ischemic attacks: subtype classification by TOAST, CCS and ASCO--a pilot study.

, 2012
BACKGROUND In patients with transient ischemic attacks (TIA), etiological classification systems are not well studied. The Trial of ORG 10172 in Acute Stroke Treatment (TOAST), the Causative Classification System (CCS), and the Atherosclerosis Small ...
Gensicke H, Amort M, Weisskopf F, Lyrer PA, Fluri F, Bonati LH, Engelter ST   +6 more
core   +1 more source

Genomic Alterations in Pulmonary Carcinoid Tumors: A Targeted Analysis of Gene Rearrangements and Oncogenic Mutations

Cancer Medicine, Volume 15, Issue 11, November 2026.
This study applied RNA‐based next‐generation sequencing to one of the largest cohorts of pulmonary carcinoid tumors analyzed to date and revealed rare yet potentially actionable gene rearrangements and variants, including alterations in ALK, BRAF, and EGFR.
Jenni Niinimäki, Soili Kytölä, Ari Ristimäki, Johanna Arola, Tiina Vesterinen   +4 more
wiley   +1 more source